by Admin | Mar 23, 2026 | News
MHRA published Field Safety Notices: 9–13 March 2026 on 17 March 2026, listing device-related notices within its alerts, recalls, and safety-information framework. The agency continues to publish these weekly summaries as part of its public safety communications....
by Admin | Mar 23, 2026 | News
FDA announced on 19 March 2026 that it approved Wegovy HD (semaglutide 7.2 mg) for weight loss and long-term weight maintenance in certain adults. The agency said the decision came 54 days after filing and marked the fourth approval under the Commissioner’s National...
by Admin | Mar 23, 2026 | News
MHRA announced on 12 March 2026 that it approved deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults. The agency also stated that, as with any medicine, it will keep the safety and effectiveness of deuruxolitinib under close review. For PV readers, the...
by Admin | Mar 23, 2026 | News
FDA says it is requesting that drug application holders remove information regarding suicidal ideation and behavior from the labeling of certain GLP-1 receptor agonist medications, specifically Saxenda, Wegovy, and Zepbound. The agency says this follows a...
by Admin | Mar 22, 2026 | News
FDA says it is requiring application holders for all drug products containing carbidopa/levodopa to add a warning that these medicines can cause vitamin B6 deficiency and vitamin B6 deficiency-associated seizures. The agency says the products are approved to treat...
by Admin | Mar 18, 2026 | Careers, News
A growing wave of concern is emerging across parts of the pharmaceutical and drug safety industry over alleged proxy interviews, false professional representation, and unethical third-party involvement in pharmacovigilance hiring. Across regulated safety functions,...
